These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 10796396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
    Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, Tugwell P, Pope J.
    Cochrane Database Syst Rev; 2017 Dec 13; 12(12):CD000467. PubMed ID: 29237099
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.
    Maltez N, Maxwell LJ, Rirash F, Tanjong Ghogomu E, Harding SE, Tingey PC, Wells GA, Tugwell P, Pope J.
    Cochrane Database Syst Rev; 2023 Nov 06; 11(11):CD014089. PubMed ID: 37929840
    [Abstract] [Full Text] [Related]

  • 8. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug 06; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

  • 9. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J, Rovenský J, Tauchmannová H, Zitnan D.
    Drugs Exp Clin Res; 1985 Aug 06; 11(9):659-63. PubMed ID: 3916837
    [Abstract] [Full Text] [Related]

  • 10. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep 06; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 11. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL.
    Cochrane Database Syst Rev; 2016 Feb 25; 2(2):CD002069. PubMed ID: 26914257
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral vasodilators for primary Raynaud's phenomenon.
    Vinjar B, Stewart M.
    Cochrane Database Syst Rev; 2008 Apr 16; (2):CD006687. PubMed ID: 18425964
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
    Roald OK, Seem E.
    Br Med J (Clin Res Ed); 1984 Sep 08; 289(6445):577-9. PubMed ID: 6432198
    [Abstract] [Full Text] [Related]

  • 16. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr 08; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 17. Oral vasodilators for primary Raynaud's phenomenon.
    Stewart M, Morling JR.
    Cochrane Database Syst Rev; 2012 Jul 11; 2012(7):CD006687. PubMed ID: 22786498
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL, Raynaud Study Investigators.
    Arthritis Rheumatol; 2017 Dec 11; 69(12):2370-2379. PubMed ID: 29193819
    [Abstract] [Full Text] [Related]

  • 19. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, Bowcock SM, Kirby JD.
    Br J Dermatol; 1987 Aug 11; 117(2):237-41. PubMed ID: 3307894
    [Abstract] [Full Text] [Related]

  • 20. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ, Murray GD, Nielsen SL.
    Am J Med; 1989 Sep 11; 87(3):264-8. PubMed ID: 2672807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.